Generate a tailored SOP for Dr. Silvia Ottaviani. Improve your application with a focused, well-structured draft.
Silvia Ottaviani's research focuses on investigating the role of non-coding RNAs, specifically microRNAs and long non-coding RNAs, in pancreatic cancer. She is particularly interested in understanding how non-coding RNAs regulate the metastatic process, which is a multi-step process involving the interplay between tumor cells and the microenvironment that results in the spread of cancer from the primary site. Pancreatic cancer is a deadly disease with high metastatic potential, and Dr. Ottaviani aims to identify novel therapeutic targets for this stage of the disease. She is also focused on identifying circulating microRNAs in the plasma and serum of cancer patients to discover novel biomarkers that can be easily translated to clinical settings. During the COVID-19 pandemic, she joined collaborative research efforts led by Professor Justin Stebbing to repurpose the drug baricitinib, which advanced COVID-19 research and led to phase 3 clinical trials and FDA approval. Dr. Ottaviani is leading a project on the discovery of microRNAs as biomarkers for COVID-19 patients. She has held a personal animal license since 2014 and has been funded through various grants.
Imperial College London, Department of Surgery and Cancer • London
Teaching and supervising students in courses related to surgery and cancer.
Imperial College London, Department of Surgery and Cancer • London
Conducting research on the role of non-coding RNAs in cancer.
Specialisms available in Materials for the Energy Transition or Theory and Simulation of Materials.